Medical Oncology

, Volume 28, Issue 4, pp 1140–1144

Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy

  • Kaan Harmankaya
  • Christa Erasim
  • Claus Koelblinger
  • Ramy Ibrahim
  • Axel Hoos
  • Hubert Pehamberger
  • Michael Binder
Original paper
  • 393 Downloads

Abstract

Malignant melanoma is an aggressive skin cancer with no effective therapies currently approved for advanced disease. In the case presented, a 55-year-old female patient diagnosed with widespread disease from amelanotic desmoplastic melanoma was treated with 10 mg/kg ipilimumab as part of a phase II clinical trial (CA184-008). Prior to ipilimumab, three chemotherapeutic regimens had failed. Ipilimumab acts as a T-cell potentiator via blockade of cytotoxic T-lymphocyte antigen-4, a negative regulator of T-cell activation. Response to ipilimumab treatment was rapid, with a substantial drop in tumor volume within 12 weeks of treatment initiation. Based on the appearance of a new subcutaneous lesion, reinduction with ipilimumab was performed at Week 30. Following reinduction, the appearance of another small new lesion made the patient ineligible, as per protocol, for further dosing despite stabilization of her remaining lesions. Ipilimumab-associated immune-related adverse events were manageable with the use of treatment guidelines. It is of remarkable immunotherapeutic importance that no new lesions emerged and gradual tumor regression is still ongoing more than 2 years following the last dose of ipilimumab, despite daily administration of systemic corticosteroids to manage drug-induced AEs. The ongoing clinical response is maintained without any further antineoplastic treatment.

Keywords

Ipilimumab Immunotherapy Melanoma Cytotoxic T-lymphocyte antigen-4 CTLA-4 Immune-related adverse events β-human chorionic gonadotropin 

Abbreviations

β-hCG

β-subunit of human chorionic gonadotropin

CTLA-4

Cytotoxic T-lymphocyte antigen-4

ECOG-PS

Eastern Cooperative Oncology Group Performance Status

irAE

Immune-related adverse event

OS

Overall survival

PD

Progressive disease

SPD

Sum of the perpendicular diameters of tumor

TSH

Thyroid-stimulating hormone

ULN

Upper limit of normal

WHO

World Health Organization

References

  1. 1.
    O’Day S, Boasberg P. Management of metastatic melanoma 2005. Surg Oncol Clin N Am. 2006;15:419–37.PubMedCrossRefGoogle Scholar
  2. 2.
    Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Jun 14 [Epub ahead of print].Google Scholar
  3. 3.
    Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ. Next generation of immunotherapy for melanoma. J Clin Oncol. 2008;26:3445–55.PubMedCrossRefGoogle Scholar
  4. 4.
    Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther. 2009;9:587–95.PubMedCrossRefGoogle Scholar
  5. 5.
    Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26:5275–83.PubMedCrossRefGoogle Scholar
  6. 6.
    Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O’Day SJ, Lebbé C. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155–64.PubMedCrossRefGoogle Scholar
  7. 7.
    Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O’Day SJ. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591–8.PubMedCrossRefGoogle Scholar
  8. 8.
    O’Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010 Feb 10. [Epub ahead of print].Google Scholar
  9. 9.
    O’Day S, Weber J, Lebbe C, Maio M, Pehamberger H, Harmankaya K, Siegel K, Hoos A, Humphrey R, Wolchok J. Effect of ipilimumab treatment on 18-month survival: update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol. 2009;27(Suppl. 15s); abstract 9033.Google Scholar
  10. 10.
    Binder M, Forstinger C, Koelbl H, Bieglmayer C. A 30-year-old woman with melanoma metastases and a positive pregnancy test. J Am Acad Dermatol. 1999;41:802–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Stenman UH, Alfthan H, Hotakainen K. Human chorionic gonadotropin in cancer. Clin Biochem. 2004;37:549–61.PubMedCrossRefGoogle Scholar
  12. 12.
    Doi F, Dorcas DJ, Chi DDJ, Charuworn BB, Conrad AJ, Russell J, Morton DL, Hoon DSB. Detection of beta-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma. Int J Cancer. 1996;65:454–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Acevedo HF, Tong JY, Hartsock RJ. Human chorionic gonadotropin-beta subunit gene expression in cultured human fetal and cancer cells of different types and origins. Cancer. 1995;76:1467–75.PubMedCrossRefGoogle Scholar
  14. 14.
    Regelson W. Have we found the “definitive cancer biomarker”? The diagnostic and therapeutic implications of human chorionic gonadotropin-beta expression as a key to malignancy. Cancer. 1995;76:1299–301.PubMedCrossRefGoogle Scholar
  15. 15.
    Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;5:7412–20.CrossRefGoogle Scholar
  16. 16.
    Weber JS, O’Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26:5950–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007;12:864–72.PubMedCrossRefGoogle Scholar
  18. 18.
    Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM. Cytotoxic T-lymphocyte associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28:593–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Chin K, Ibrahim R, Berman D, Yellin M, Lowy I, Lin R, Hoos A. Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab, an anti-CTLA-4 therapy. Ann Oncol. 2008;19(Suppl. 8): 787.Google Scholar
  20. 20.
    Lin R, Yellin MJ, Lowy I, Safferman A, Chin K, Ibrahim R. An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: prevention of gastrointestinal perforation and/or colectomy. J Clin Oncol. 2008;26(Suppl.):abstract 9063.Google Scholar
  21. 21.
    Amin A, DePril V, Hamid O, Wolchok J, Maio M, Neyns B, Chin K, Ibrahim R, Hoos A, O’Day S. Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity. J Clin Oncol. 2009;27:15s, suppl; abstr 9037.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Kaan Harmankaya
    • 1
  • Christa Erasim
    • 1
  • Claus Koelblinger
    • 2
  • Ramy Ibrahim
    • 3
  • Axel Hoos
    • 3
  • Hubert Pehamberger
    • 1
  • Michael Binder
    • 1
  1. 1.Department of Dermatology, Division of General DermatologyMedical University of ViennaViennaAustria
  2. 2.Department of RadiologyMedical University of ViennaViennaAustria
  3. 3.Bristol-Myers Squibb CompanyWallingfordUSA

Personalised recommendations